Centralised/DCP/MRP procedures, EMA committees, and EU regulatory processes
19 terms
EMA committee that assesses quality, safety, and efficacy of advanced therapy medicinal products (ATMPs) and provides recommendations within the centralised procedure.
An EU marketing authorisation route where a single application to EMA leads to one marketing authorisation valid across EU/EEA (for eligible products).
EMA committee responsible for preparing opinions on questions concerning medicines for human use, including assessment of marketing authorisation applications under the centralised procedure.
A coordination group facilitating harmonised decisions for human medicines assessed via mutual recognition and decentralised procedures in the EU.